AVERIN CAPITAL LLC

Thesis

Averin Capital is a venture capital firm, also described as a company creation and multi-stage investment firm, founded in 2023 and formerly known as Bedford Bridge. Its core investment thesis is centered on the convergence of technology and biology to drive advancements in healthcare. The firm strategically focuses on four key verticals: Deep Technology (including synthetic biology, nanotechnology, personalized medicine, and genomics), Artificial Intelligence (for therapeutic development, diagnostics, decision support, workflow optimization, insurance, and predictive analytics), Longevity (targeting early screening, preventative care, remote patient monitoring, and integrated care platforms), and Data-Driven Care (encompassing value-based care, real-world data and evidence, payment integrity, and sustainable healthcare models). Averin Capital operates across multiple stages of company development and primarily focuses on North America, with opportunistic investments considered in Europe and Asia. While some sources suggest a single-family office structure, its active investment approach and public-facing acquisition vehicle indicate a broader VC operational model. The firm's headquarters are in New York, NY, though AZBio lists its founding in 2024 with headquarters in Scottsdale, AZ. The provided office address for Averin Capital Acquisition Corp. is in Andover, MA.

Related lists

• Pre-seed AI investors
• Seed-stage AI investors
• Series A AI investors